Massive study of 2 million AF patients reveals Real-World impact of blood thinners

NCT ID NCT05838664

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study analyzed data from over 2 million people in France with atrial fibrillation (an irregular heart rhythm) to compare outcomes between those who took blood thinners and those who did not. Researchers looked at rates of stroke, major bleeding, and death between 2016 and 2020 using a national health database. The goal was to understand how well these medications work in everyday practice, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oral anticoagulants (blood thinners: apixaban, rivaroxaban, dabigatran, warfarin)
What this could lead to
If successful, this study could help doctors better understand the real-world benefits and risks of blood thinners for atrial fibrillation patients, potentially improving treatment guidelines.
What could go wrong
This is a retrospective study using existing data, not a controlled experiment. It can show patterns but cannot prove cause and effect. Results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer Investigational Site

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.